Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors.

Journal Article

Photodynamic therapy (PDT) ablates malignancies by applying focused near-infrared (nIR) light onto a lesion of interest after systemic administration of a photosensitizer (PS); however, the accumulation of existing PS is not tumor-exclusive. We developed a tumor-localizing strategy for PDT, exploiting the high expression of heat shock protein 90 (Hsp90) in cancer cells to retain high concentrations of PS by tethering a small molecule Hsp90 inhibitor to a PS (verteporfin, VP) to create an Hsp90-targeted PS (HS201). HS201 accumulates to a greater extent than VP in breast cancer cells both in vitro and in vivo, resulting in increased treatment efficacy of HS201-PDT in various human breast cancer xenografts regardless of molecular and clinical subtypes. The therapeutic index achieved with Hsp90-targeted PDT would permit treatment not only of localized tumors, but also more diffusely infiltrating processes such as inflammatory breast cancer.

Full Text

Duke Authors

Cited Authors

  • Kaneko, K; Osada, T; Morse, MA; Gwin, WR; Ginzel, JD; Snyder, JC; Yang, X-Y; Liu, C-X; Diniz, MA; Bodoor, K; Hughes, PF; Haystead, TA; Lyerly, HK

Published Date

  • May 8, 2020

Published In

Volume / Issue

  • 3 / 1

Start / End Page

  • 226 -

PubMed ID

  • 32385408

Pubmed Central ID

  • 32385408

Electronic International Standard Serial Number (EISSN)

  • 2399-3642

Digital Object Identifier (DOI)

  • 10.1038/s42003-020-0956-7


  • eng

Conference Location

  • England